




Leading Companies - Advanced AI in Healthcare and Drug Discovery 2019 / Q3



460 Investors	200 Companies	35 R&D Centers	25 AI Tech Corporations	30 AI Pharma Corporations	15 Chemical Corporations
------------------	------------------	-------------------	----------------------------	------------------------------	-----------------------------

The rapid development of the industry continues, following the trend mentioned in our previous report about Q2 2019. Now not only are private investors getting interested in AI for Drug Discovery companies, but the Biopharmaceutical companies are looking for cooperation with AI startups on their own. In Q3 2019 460 investors were identified. Companies, Corporations, and R&D Centers demonstrated a growing interest in the industry as well. The report also highlights 30 Pharma corporations applying AI for drug discovery and 25 Tech corporations and 15 Chemical Corporations applying advanced AI applications in healthcare.

This 145-page "AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2019 / Q3" report marks the eighth installment in Deep Knowledge Analytics Pharma Division's landmark series of reports on the topic of Artificial Intelligence in Drug Discovery, first begun in 2017. These reports are released on a quarterly basis, and are designed to provide an overview of the industry landscape, to reveal trends and correlations, and to benchmark the performance of key industry players and participants.

About the Report

The present edition consists of an updated overview of the industry state in Q3 of 2019, tuned to the latter half of 2019 and including extended coverage of major events in Q3 of 2019. It revisits the major insights, data analytics and forecasts of our previous report, analyzing existing trends and conclusions that are still on track, which ones have changed their course, and which ones have been usurped by entirely new realities of our changing world. This report is constructed to provide industry professionals with the tools, frameworks, solutions and insights necessary to gain a tangible understand what is happening in the industry, including its current state and near-future trajectory, to more relevantly structure their strategic agendas.

Summary

This report applied sophisticated multidimensional analytical frameworks to assess and benchmark pharma and tech corporations according to level their level of commitment in applying AI methods and tools in their business models, products and services in an integral and non-superficial way, with a strong emphasis on the overall level of advancement in the AI techniques and technologies they are on-boarding and applying. We assume that future reports will reveal a correlation between the results of such benchmarking and the market and investment prospects of pharma and tech corporations, and that the level of AI-commitment can serve as an indicator of market capitalization growth.

AI for Drug Discovery,
Biomarker Development
and Advanced R&D
Landscape / 2019 Q3

AI Companies - 200
Investors - 460
Corporations - 70



Pharma AI Deals Structure 2019 / 30 Pharma Corporations

AI Companies	Pharma Corporations	Pharma Corporations	AI Companies
BenevolentAI, BERG, Alibaba Group, Tencent 腾讯	AstraZeneca	Pfizer	Biovista, XtalPi, Recursion, Atomwise, 5
Insilico Medicine 英科智能, CloudPharmaceuticals, Exscientia	gsk	Takeda	WAVE, Insilico Medicine 英科智能, GeneTech, RECURSION
Atomwise, turbine, CYCLICA	Merck	SANOFI	BERG, Exscientia, Researchably
Atomwise, IKTOS, CYCLICA	Roche	AMGEN	GNS HEALTHCARE, GeneTech
Genialis, Exscientia	Novartis	abbvie	WuXi AppTec, Atomwise
sirenas, Concerto HealthAI	Bristol-Myers Squibb	NOVARTIS	BenevolentAI, Biovista
5, e-therapeutics, turbine	Novo Nordisk	Celgene	Exscientia
	Johnson & Johnson	Boehringer Ingelheim	NANNA
	evotec	astellas	Biovista
	Sanitomo Danippon Pharma	Genentech	
	Biogen	DAEWONG	
	teva	illumina	
	GILEAD	IPSEN	
		Santen	
	agios		

Pharma corporations have a substantial interest in AI-driven companies in terms of R&D partnerships and M&A deals. **AstraZeneca** and **Pfizer** made the biggest number of significant AI and Drug Discovery deals. All of the deals were categorized as the ones aiming to save costs and increase operational efficiency.